Bicycle Therapeutics Q1 net loss $39.1M; cash $293.8M; Novartis deal advances BRC pipeline

BICYCLE THERAPEUTICS PLC

2023-Q1 EPS reported -$1.30 revenue$4,896,000

Net loss of $39.1M ($1.30 per share) vs $27.6M ($0.93 per share) in Q1 2022.
R&D expenses rose to $32.2M from $14.3M, driven by BT8009, BT5528, and TICA programs.
Cash $293.8M at March 31, 2023 (excluding $50M Novartis upfront); runway into 2025.
Entered Novartis collaboration for Bicycle radio-conjugates; eligible for up to $1.7B milestones.
BT8009 Phase I dose escalation showed median duration of response ~14 months in urothelial cancer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BICYCLE THERAPEUTICS PLC reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-23-055781

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.